ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for estrogens, conjugated; medroxyprogesterone acetate and what is the scope of patent protection?
Estrogens, conjugated; medroxyprogesterone acetate
is the generic ingredient in four branded drugs marketed by Wyeth Pharms Inc and Wyeth Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 6 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE |
| DailyMed Link: | ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE at DailyMed |
Recent Clinical Trials for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Far Eastern Memorial Hospital | Phase 4 |
| Selmo Geber | N/A |
| Organon | Phase 4 |
See all ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE clinical trials
Pharmacology for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
| Drug Class | Estrogen Progestin |
| Mechanism of Action | Estrogen Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
US Patents and Regulatory Information for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPRO | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-004 | Mar 12, 2003 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | PREMPRO | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-003 | Jan 9, 1998 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | PREMPRO | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-005 | Jun 4, 2003 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms Inc | PREMPHASE (PREMARIN;CYCRIN 14/14) | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020303-002 | Dec 30, 1994 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPRO | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-003 | Jan 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Pharms | PREMPRO | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-001 | Nov 17, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Pharms | PREMPRO | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-001 | Nov 17, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Pharms Inc | PREMPHASE (PREMARIN;CYCRIN 14/14) | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020303-002 | Dec 30, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Pharms Inc | PREMPRO (PREMARIN;CYCRIN) | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020303-001 | Dec 30, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
